Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolution of clinical agents for ovulation induction

M J Gast1

  • 1Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110.

American Journal of Obstetrics and Gynecology
|February 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial.

Neurology·2007
Same author

A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol.

American journal of obstetrics and gynecology·1999
Same author

Regulation of creatine kinase isoenzymes in human placenta during early, mid-, and late gestation.

Journal of the Society for Gynecologic Investigation·1996
Same author

The evolution of new agents for ovulation induction.

Seminars in reproductive endocrinology·1996
Same author

Endometrial thickness is a valid monitoring parameter in cycles of ovulation induction with menotropins alone.

Fertility and sterility·1996
Same author

Future of the hamster oocyte penetration assay?

Fertility and sterility·1995

Newer ovulation induction therapies are emerging, including advanced gonadotropins and non-gonadotropin treatments. These innovations promise to significantly change fertility treatments by the end of the decade.

Area of Science:

  • Reproductive Endocrinology
  • Pharmacology

Background:

  • Ovulation induction therapies have seen limited innovation since the 1960s.
  • Current gonadotropin therapy options are relatively static.

Purpose of the Study:

  • To review emerging and novel ovulation induction therapies.
  • To discuss the future landscape of fertility treatments.

Main Methods:

  • Literature review of recent advancements in ovulation induction.
  • Analysis of novel gonadotropin preparations and non-gonadotropin adjuncts.

Main Results:

  • Introduction of highly purified and recombinant follicle-stimulating hormone (FSH), luteinizing hormone (LH), and human chorionic gonadotropin (hCG).
  • Exploration of protein fragments, cytokines, and growth factors as ovulation adjuncts.

Related Experiment Videos

  • Investigation into genetically engineered gonadotropins, chimeric proteins, and gene therapy.

    • Conclusions:

    • The field of ovulation induction is poised for rapid advancement.
    • Future therapies will likely include novel gonadotropins and non-gonadotropin approaches.
    • These innovations are expected to significantly impact fertility treatments.